25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Amneal Pharmaceuticals, Inc. Class A Common Stock
Buy, Hold or Sell?

Let's analyze Amneal together

I guess you are interested in Amneal Pharmaceuticals, Inc. Class A Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Amneal Pharmaceuticals, Inc. Class A Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Amneal Pharmaceuticals, Inc. Class A Common Stock

I send you an email if I find something interesting about Amneal Pharmaceuticals, Inc. Class A Common Stock.

1. Quick Overview

1.1. Quick analysis of Amneal (30 sec.)










1.2. What can you expect buying and holding a share of Amneal? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
31.3%

What is your share worth?

Current worth
$-0.30
Expected worth in 1 year
$-1.22
How sure are you?
43.8%

+ What do you gain per year?

Total Gains per Share
$-0.92
Return On Investment
-10.7%

For what price can you sell your share?

Current Price per Share
$8.57
Expected price per share
$6.5 - $9.475
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Amneal (5 min.)




Live pricePrice per Share (EOD)
$8.57

2.2. Growth of Amneal (5 min.)




Is Amneal growing?

Current yearPrevious yearGrowGrow %
How rich?-$93.5m$186.3m-$209.9m-891.0%

How much money is Amneal making?

Current yearPrevious yearGrowGrow %
Making money-$43.1m$1.4m-$44.5m-103.3%
Net Profit Margin-6.8%0.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Amneal (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Amneal?

Welcome investor! Amneal's management wants to use your money to grow the business. In return you get a share of Amneal.

First you should know what it really means to hold a share of Amneal. And how you can make/lose money.

Speculation

The Price per Share of Amneal is $8.57. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Amneal.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Amneal, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.30. Based on the TTM, the Book Value Change Per Share is $-0.23 per quarter. Based on the YOY, the Book Value Change Per Share is $0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Amneal.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.040.4%-0.14-1.6%0.010.1%-0.04-0.4%-0.04-0.4%
Usd Book Value Change Per Share-0.29-3.4%-0.23-2.7%0.141.6%-0.08-0.9%-0.01-0.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.080.9%
Usd Total Gains Per Share-0.29-3.4%-0.23-2.7%0.141.6%-0.08-0.9%0.070.8%
Usd Price Per Share8.32-6.70-2.68-4.52-8.29-
Price to Earnings Ratio54.82-32.35-0.71--15.93--13.06-
Price-to-Total Gains Ratio-28.77-16.11-48.56--21.12--11.92-
Price to Book Ratio-27.55--136.16-4.42--22.70--17.02-
Price-to-Total Gains Ratio-28.77-16.11-48.56--21.12--11.92-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.57
Number of shares116
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.23-0.08
Usd Total Gains Per Share-0.23-0.08
Gains per Quarter (116 shares)-26.67-9.16
Gains per Year (116 shares)-106.68-36.63
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-107-1170-37-47
20-213-2240-73-84
30-320-3310-110-121
40-427-4380-147-158
50-533-5450-183-195
60-640-6520-220-232
70-747-7590-256-269
80-853-8660-293-306
90-960-9730-330-343
100-1067-10800-366-380

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%4.08.00.033.3%7.013.00.035.0%11.021.00.034.4%11.021.00.034.4%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%8.012.00.040.0%11.019.02.034.4%11.019.02.034.4%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%10.00.022.031.3%10.00.022.031.3%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%8.012.00.040.0%14.018.00.043.8%14.018.00.043.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Amneal Pharmaceuticals, Inc. Class A Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.289-0.230-21%0.136-312%-0.079-73%-0.009-97%
Book Value Per Share---0.302-0.076-75%0.601-150%0.741-141%0.766-139%
Current Ratio--1.3821.499-8%1.869-26%1.968-30%1.900-27%
Debt To Asset Ratio--1.0271.007+2%0.950+8%0.942+9%0.972+6%
Debt To Equity Ratio---43.635-100%22.810-100%20.381-100%5398785.928-100%
Dividend Per Share----0%0.000-100%0.000-100%0.080-100%
Eps--0.038-0.139+467%0.008+356%-0.035+193%-0.037+197%
Gross Profit Margin--1.0001.0000%1.0000%1.121-11%1.076-7%
Market Cap2655363080.000+3%2577902080.0002090421687.500+23%828832700.000+211%1402768569.500+84%2568962727.188+0%
Net Profit Margin--0.017-0.068+509%0.002+759%-0.030+276%-0.030+279%
Operating Margin---0.064-100%0.133-100%0.063-100%0.082-100%
Operating Ratio--0.8720.892-2%0.891-2%0.918-5%0.899-3%
Pb Ratio-28.379-3%-27.551-136.158+394%4.423-723%-22.700-18%-17.015-38%
Pe Ratio56.463+3%54.81632.351+69%0.707+7650%-15.933+129%-13.058+124%
Price Per Share8.570+3%8.3206.700+24%2.675+211%4.518+84%8.285+0%
Price To Free Cash Flow Ratio---0.762-100%-2.2360%1.420-100%7.525-100%
Price To Total Gains Ratio-29.630-3%-28.76616.110-279%48.564-159%-21.124-27%-11.918-59%
Quick Ratio--0.7510.821-9%1.012-26%1.168-36%1.155-35%
Return On Assets--0.003-0.012+467%0.000+793%-0.005+241%-0.001+115%
Return On Equity----1.2470%0.009-100%-0.3070%161046.644-100%
Total Gains Per Share---0.289-0.230-21%0.136-312%-0.079-73%0.070-511%
Usd Book Value---93567000.000-23557500.000-75%186344250.000-150%229665700.000-141%237215406.250-139%
Usd Book Value Change Per Share---0.289-0.230-21%0.136-312%-0.079-73%-0.009-97%
Usd Book Value Per Share---0.302-0.076-75%0.601-150%0.741-141%0.766-139%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.080-100%
Usd Eps--0.038-0.139+467%0.008+356%-0.035+193%-0.037+197%
Usd Free Cash Flow---27041000.000-100%34374750.000-100%35063300.000-100%29356906.250-100%
Usd Market Cap2655363080.000+3%2577902080.0002090421687.500+23%828832700.000+211%1402768569.500+84%2568962727.188+0%
Usd Price Per Share8.570+3%8.3206.700+24%2.675+211%4.518+84%8.285+0%
Usd Profit--11757000.000-43135250.000+467%1411750.000+733%-17313500.000+247%-19494718.719+266%
Usd Revenue--702468000.000670105000.000+5%596596250.000+18%557643500.000+26%480535500.000+46%
Usd Total Gains Per Share---0.289-0.230-21%0.136-312%-0.079-73%0.070-511%
 EOD+4 -3MRQTTM+12 -16YOY+12 -185Y+13 -1810Y+13 -19

3.3 Fundamental Score

Let's check the fundamental score of Amneal Pharmaceuticals, Inc. Class A Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1556.463
Price to Book Ratio (EOD)Between0-1-28.379
Net Profit Margin (MRQ)Greater than00.017
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.751
Current Ratio (MRQ)Greater than11.382
Debt to Asset Ratio (MRQ)Less than11.027
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.003
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Amneal Pharmaceuticals, Inc. Class A Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.592
Ma 20Greater thanMa 508.546
Ma 50Greater thanMa 1008.524
Ma 100Greater thanMa 2008.222
OpenGreater thanClose8.285
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Amneal Pharmaceuticals, Inc. Class A Common Stock

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Fundamental data was last updated by Penke on 2024-11-16 12:48:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Amneal earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 1.7% means that $0.02 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 1.7%. The company is making a profit. +1
  • The TTM is -6.8%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ1.7%TTM-6.8%+8.5%
TTM-6.8%YOY0.2%-7.0%
TTM-6.8%5Y-3.0%-3.9%
5Y-3.0%10Y-3.0%+0.0%
4.3.1.2. Return on Assets

Shows how efficient Amneal is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.3% Return on Assets means that Amneal generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 0.3%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -1.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.3%TTM-1.2%+1.6%
TTM-1.2%YOY0.0%-1.3%
TTM-1.2%5Y-0.5%-0.8%
5Y-0.5%10Y-0.1%-0.4%
4.3.1.3. Return on Equity

Shows how efficient Amneal is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Amneal generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-124.7%+124.7%
TTM-124.7%YOY0.9%-125.6%
TTM-124.7%5Y-30.7%-94.0%
5Y-30.7%10Y16,104,664.4%-16,104,695.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Amneal Pharmaceuticals, Inc. Class A Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Amneal is operating .

  • Measures how much profit Amneal makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM6.4%-6.4%
TTM6.4%YOY13.3%-6.9%
TTM6.4%5Y6.3%+0.0%
5Y6.3%10Y8.2%-1.9%
4.3.2.2. Operating Ratio

Measures how efficient Amneal is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.87 means that the operating costs are $0.87 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 0.872. The company is less efficient in keeping operating costs low.
  • The TTM is 0.892. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.872TTM0.892-0.020
TTM0.892YOY0.891+0.001
TTM0.8925Y0.918-0.026
5Y0.91810Y0.899+0.019
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Amneal Pharmaceuticals, Inc. Class A Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Amneal is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.38 means the company has $1.38 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 1.382. The company is just able to pay all its short-term debts.
  • The TTM is 1.499. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.382TTM1.499-0.117
TTM1.499YOY1.869-0.370
TTM1.4995Y1.968-0.469
5Y1.96810Y1.900+0.068
4.4.3.2. Quick Ratio

Measures if Amneal is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.75 means the company can pay off $0.75 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 0.751. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.821. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.751TTM0.821-0.070
TTM0.821YOY1.012-0.191
TTM0.8215Y1.168-0.347
5Y1.16810Y1.155+0.013
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Amneal Pharmaceuticals, Inc. Class A Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Amneal assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Amneal to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 1.03 means that Amneal assets are financed with 102.7% credit (debt) and the remaining percentage (100% - 102.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 1.027. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.007. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.027TTM1.007+0.020
TTM1.007YOY0.950+0.057
TTM1.0075Y0.942+0.065
5Y0.94210Y0.972-0.030
4.5.4.2. Debt to Equity Ratio

Measures if Amneal is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM43.635-43.635
TTM43.635YOY22.810+20.825
TTM43.6355Y20.381+23.254
5Y20.38110Y5,398,785.928-5,398,765.546
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Amneal generates.

  • Above 15 is considered overpriced but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 54.82 means the investor is paying $54.82 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The EOD is 56.463. Based on the earnings, the company is expensive. -2
  • The MRQ is 54.816. Based on the earnings, the company is expensive. -2
  • The TTM is 32.351. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD56.463MRQ54.816+1.647
MRQ54.816TTM32.351+22.466
TTM32.351YOY0.707+31.643
TTM32.3515Y-15.933+48.284
5Y-15.93310Y-13.058-2.875
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.762-0.762
TTM0.762YOY-2.236+2.998
TTM0.7625Y1.420-0.658
5Y1.42010Y7.525-6.106
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Amneal is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of -27.55 means the investor is paying $-27.55 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The EOD is -28.379. Based on the equity, the company is expensive. -2
  • The MRQ is -27.551. Based on the equity, the company is expensive. -2
  • The TTM is -136.158. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-28.379MRQ-27.551-0.828
MRQ-27.551TTM-136.158+108.607
TTM-136.158YOY4.423-140.581
TTM-136.1585Y-22.700-113.458
5Y-22.70010Y-17.015-5.685
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Amneal Pharmaceuticals, Inc. Class A Common Stock.

4.8.1. Institutions holding Amneal Pharmaceuticals, Inc. Class A Common Stock

Institutions are holding 46.237% of the shares of Amneal Pharmaceuticals, Inc. Class A Common Stock.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30UBS Group AG7.05860.0343218495232167136512164.1268
2024-06-30Vanguard Group Inc4.52090.0017139941782659451.9372
2024-06-30TPG GP A, LLC3.98291.7951232876700
2024-06-30BlackRock Inc3.64490.001611282430211825823.1146
2024-06-30Rubric Capital Management LP3.46371.785210721778117983012.3647
2024-06-30Citadel Advisors Llc3.22690.012899887257299995271.5035
2024-06-30Nantahala Capital Management, LLC1.72510.994153398862719943103.8169
2024-06-30Fosun International Ltd1.5049.97544655403-7658845-62.195
2024-06-30Dimensional Fund Advisors, Inc.1.3840.0071428392864140517.6088
2024-06-30Neuberger Berman Group LLC1.15280.01863568353-352622-8.9932
2024-06-30Geode Capital Management, LLC1.10120.0019340853563548522.9165
2024-06-30State Street Corp1.09420.0009338696844277015.0387
2024-06-30Nuveen Asset Management, LLC0.81780.0047253136957316229.2697
2024-06-30Morgan Stanley - Brokerage Accounts0.66910.000520712101592868.3312
2024-06-30BlackBarn Capital Partners LP0.64611.1288200000058670341.5131
2024-09-30Hennessy Advisors, Inc.0.50530.4167156400017540012.6314
2024-06-30Goldman Sachs Group Inc0.4460.0015138041268792699.3415
2024-06-30Woodline Partners LP0.42480.0797131502362691791.1076
2024-06-30Northern Trust Corp0.40470.00131252852-14332-1.131
2024-09-30Assenagon Asset Management SA0.38930.01851204994642065114.0579
Total 38.162316.2803118128334+32400656+27.4%

4.9.2. Funds holding Amneal Pharmaceuticals, Inc. Class A Common Stock

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Total Stock Mkt Idx Inv1.40760.0021435726300
2024-10-31iShares Russell 2000 ETF1.34280.05194156541-9352-0.2245
2024-09-30Vanguard Small Cap Index1.12810.01893491925-17236-0.4912
2024-09-30Vanguard Small Cap Value Index Inv0.76280.0335236103815890.0673
2024-09-30Vanguard Institutional Extnd Mkt Idx Tr0.69840.0165216184838885421.9321
2024-08-31Fidelity Small Cap Index0.52460.05161623952-44403-2.6615
2024-09-30Hennessy Cornerstone Growth Investor0.50532.508156400017540012.6314
2024-08-31CREF Stock R10.42450.0088131415000
2024-10-31iShares Russell 2000 Growth ETF0.38210.0844118281600
2024-09-30Columbia Small Cap Value II Inst0.37920.9643117393027059029.9544
2024-09-30Columbia Small Cap Value II0.37920.9635117393011739300
2024-10-31Invesco Pharmaceuticals ETF0.35573.3214110118400
2024-09-30Neuberger Berman Intrinsic Value I0.34140.6971105685400
2024-09-30Nuveen Quant Small Cap Equity R60.33470.2453103619000
2024-06-30Phocas Small Cap Value Equity0.30250.973793626433021254.4858
2024-10-31State St Russell Sm/Mid CpÂŽ Indx NL Cl C0.29150.017902381-32700-3.497
2024-09-30Fidelity Extended Market Index0.27810.017286081716509923.7307
2024-09-30DFA US Small Cap I0.27030.041583659800
2024-10-31Invesco Dorsey Wright SmallCap Momt ETF0.23950.646774120900
2024-09-30Vanguard Russell 2000 ETF0.23560.04887292488566713.311
Total 10.583910.712232762138+2487650+7.6%

5.3. Insider Transactions

Insiders are holding 53.359% of the shares of Amneal Pharmaceuticals, Inc. Class A Common Stock.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-11Andrew S BoyerSELL293024.13
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets3,460,978
Total Liabilities3,554,545
Total Stockholder Equity-93,567
 As reported
Total Liabilities 3,554,545
Total Stockholder Equity+ -93,567
Total Assets = 3,460,978

Assets

Total Assets3,460,978
Total Current Assets1,513,294
Long-term Assets1,947,684
Total Current Assets
Cash And Cash Equivalents 74,006
Net Receivables 748,055
Inventory 596,359
Other Current Assets 94,874
Total Current Assets  (as reported)1,513,294
Total Current Assets  (calculated)1,513,294
+/-0
Long-term Assets
Property Plant Equipment 532,897
Goodwill 598,324
Intangible Assets 780,189
Long-term Assets Other 36,274
Long-term Assets  (as reported)1,947,684
Long-term Assets  (calculated)1,947,684
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,095,209
Long-term Liabilities2,399,449
Total Stockholder Equity-93,567
Total Current Liabilities
Short-term Debt 241,021
Other Current Liabilities 854,188
Total Current Liabilities  (as reported)1,095,209
Total Current Liabilities  (calculated)1,095,209
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)2,399,449
Long-term Liabilities  (calculated)0
+/- 2,399,449
Total Stockholder Equity
Total Stockholder Equity (as reported)-93,567
Total Stockholder Equity (calculated)0
+/- 93,567
Other
Cash and Short Term Investments 74,006
Common Stock Shares Outstanding 309,647
Liabilities and Stockholders Equity 3,460,978
Net Debt 2,430,655
Net Working Capital 418,085
Short Long Term Debt Total 2,504,661



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
1,218,817
1,218,817
1,218,817
1,239,611
1,341,889
1,358,788
4,544,588
4,582,048
4,352,736
4,384,586
4,262,139
3,703,943
3,665,890
4,390,800
4,056,756
4,037,536
4,006,033
3,960,070
4,023,053
3,974,409
3,939,664
3,888,968
4,041,405
3,874,039
3,799,341
3,626,605
3,700,886
3,687,079
3,472,569
3,456,397
3,509,922
3,460,978
3,460,9783,509,9223,456,3973,472,5693,687,0793,700,8863,626,6053,799,3413,874,0394,041,4053,888,9683,939,6643,974,4094,023,0533,960,0704,006,0334,037,5364,056,7564,390,8003,665,8903,703,9434,262,1394,384,5864,352,7364,582,0484,544,5881,358,7881,341,8891,239,6111,218,8171,218,8171,218,817
   > Total Current Assets 
726,114
31,721
0
693,513
771,933
48,200
1,347,894
1,431,301
1,286,644
1,267,968
1,185,847
1,205,831
1,210,210
1,773,700
1,480,874
1,543,719
1,551,539
1,559,661
1,563,475
1,570,337
1,520,108
1,389,678
1,553,601
1,419,832
1,411,818
1,307,325
1,421,789
1,456,075
1,377,863
1,380,044
1,485,480
1,513,294
1,513,2941,485,4801,380,0441,377,8631,456,0751,421,7891,307,3251,411,8181,419,8321,553,6011,389,6781,520,1081,570,3371,563,4751,559,6611,551,5391,543,7191,480,8741,773,7001,210,2101,205,8311,185,8471,267,9681,286,6441,431,3011,347,89448,200771,933693,513031,721726,114
       Cash And Cash Equivalents 
27,367
-31,721
0
19,348
74,166
48,200
61,521
165,192
213,394
63,946
54,893
212,738
151,197
405,238
266,143
281,278
341,378
452,097
278,306
302,655
247,790
210,477
91,979
87,335
25,976
144,674
109,284
86,929
91,542
46,520
43,769
74,006
74,00643,76946,52091,54286,929109,284144,67425,97687,33591,979210,477247,790302,655278,306452,097341,378281,278266,143405,238151,197212,73854,89363,946213,394165,19261,52148,20074,16619,3480-31,72127,367
       Short-term Investments 
4,354
63,442
0
0
1,851
0
2,310
1,617
2,142
0
0
0
1,123
373
2,805
700
1,696
0
1,303
2,113
1,174
1,595
1,694
2,168
1,821
3,306
3,360
0
0
0
3,446
0
03,4460003,3603,3061,8212,1681,6941,5951,1742,1131,30301,6967002,8053731,1230002,1421,6172,31001,8510063,4424,354
       Net Receivables 
407,351
0
0
340,071
382,727
349,180
714,992
735,099
482,325
641,368
637,136
520,247
606,157
889,690
720,756
743,346
640,302
531,702
718,266
629,261
663,762
610,100
690,187
630,433
742,291
545,790
674,885
692,550
645,660
704,051
803,378
748,055
748,055803,378704,051645,660692,550674,885545,790742,291630,433690,187610,100663,762629,261718,266531,702640,302743,346720,756889,690606,157520,247637,136641,368482,325735,099714,992349,180382,727340,07100407,351
       Inventory 
266,161
0
0
277,745
284,038
327,886
512,479
490,768
457,219
448,294
414,627
401,827
381,067
437,959
443,956
475,760
490,649
497,008
523,385
520,245
489,389
512,241
533,028
543,858
530,735
529,042
550,558
576,474
581,384
570,653
575,624
596,359
596,359575,624570,653581,384576,474550,558529,042530,735543,858533,028512,241489,389520,245523,385497,008490,649475,760443,956437,959381,067401,827414,627448,294457,219490,768512,479327,886284,038277,74500266,161
       Other Current Assets 
10,179
0
0
56,349
31,002
50,174
58,902
40,242
128,321
111,563
77,062
66,699
70,164
40,813
50,019
43,335
73,467
75,137
43,518
110,212
110,218
56,860
201,988
128,642
103,565
81,424
81,764
91,444
91,205
93,916
96,216
94,874
94,87496,21693,91691,20591,44481,76481,424103,565128,642201,98856,860110,218110,21243,51875,13773,46743,33550,01940,81370,16466,69977,062111,563128,32140,24258,90250,17431,00256,3490010,179
   > Long-term Assets 
481,774
0
0
529,083
569,956
564,451
3,196,694
3,150,747
3,066,092
3,116,618
3,076,292
2,498,112
2,455,680
2,617,100
2,575,882
2,493,817
2,454,494
2,400,409
2,459,578
2,404,072
2,419,556
2,499,290
2,487,804
2,454,207
2,387,523
2,319,280
2,279,097
2,231,004
2,094,706
2,076,353
2,024,442
1,947,684
1,947,6842,024,4422,076,3532,094,7062,231,0042,279,0972,319,2802,387,5232,454,2072,487,8042,499,2902,419,5562,404,0722,459,5782,400,4092,454,4942,493,8172,575,8822,617,1002,455,6802,498,1123,076,2923,116,6183,066,0923,150,7473,196,694564,451569,956529,08300481,774
       Property Plant Equipment 
407,404
0
0
457,617
486,758
489,947
569,328
567,498
544,146
658,457
647,605
624,033
609,153
611,453
606,072
600,895
595,169
595,136
597,946
459,651
639,003
622,636
602,770
587,436
589,360
578,377
571,275
560,799
550,137
544,785
528,937
532,897
532,897528,937544,785550,137560,799571,275578,377589,360587,436602,770622,636639,003459,651597,946595,136595,169600,895606,072611,453609,153624,033647,605658,457544,146567,498569,328489,947486,758457,61700407,404
       Goodwill 
28,441
0
0
26,005
26,444
26,338
386,475
410,616
426,226
421,640
420,017
419,671
419,504
514,733
527,475
522,690
522,814
522,758
549,091
566,406
593,017
602,893
600,974
599,504
598,853
599,156
599,206
598,631
598,629
598,549
598,533
598,324
598,324598,533598,549598,629598,631599,206599,156598,853599,504600,974602,893593,017566,406549,091522,758522,814522,690527,475514,733419,504419,671420,017421,640426,226410,616386,47526,33826,44426,0050028,441
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
16,373
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000016,373000000000000
       Intangible Assets 
45,929
0
0
45,461
44,599
48,166
1,788,533
1,733,020
1,654,969
1,591,158
1,553,330
1,435,801
1,382,753
1,475,161
1,423,826
1,349,113
1,304,626
1,262,954
1,293,325
1,232,727
1,166,922
1,209,818
1,204,224
1,159,005
1,096,093
1,055,319
1,015,376
982,531
890,423
859,272
819,944
780,189
780,189819,944859,272890,423982,5311,015,3761,055,3191,096,0931,159,0051,204,2241,209,8181,166,9221,232,7271,293,3251,262,9541,304,6261,349,1131,423,8261,475,1611,382,7531,435,8011,553,3301,591,1581,654,9691,733,0201,788,53348,16644,59945,4610045,929
       Other Assets 
10,929
0
0
17,015
12,155
746,137
452,358
439,613
440,751
445,363
455,340
15,607
16,455
15,753
18,509
21,119
149,300
19,561
19,216
145,288
473,696
21,792
79,836
108,262
17,631
0
13,612
0
0
0
0
0
0000013,612017,631108,26279,83621,792473,696145,28819,21619,561149,30021,11918,50915,75316,45515,607455,340445,363440,751439,613452,358746,13712,15517,0150010,929
> Total Liabilities 
1,394,762
0
0
1,665,821
1,717,471
1,727,607
3,605,102
3,666,729
3,456,373
3,584,805
3,512,787
3,308,219
3,319,102
3,987,342
3,685,740
3,689,340
3,661,101
3,593,362
3,632,781
3,591,243
3,572,691
3,481,561
3,850,529
3,851,664
3,590,413
3,464,410
3,518,012
3,495,699
3,452,558
3,473,004
3,513,989
3,554,545
3,554,5453,513,9893,473,0043,452,5583,495,6993,518,0123,464,4103,590,4133,851,6643,850,5293,481,5613,572,6913,591,2433,632,7813,593,3623,661,1013,689,3403,685,7403,987,3423,319,1023,308,2193,512,7873,584,8053,456,3733,666,7293,605,1021,727,6071,717,4711,665,821001,394,762
   > Total Current Liabilities 
225,073
0
0
259,237
296,883
313,051
669,736
749,271
553,850
599,530
546,159
534,910
550,406
965,065
655,019
667,886
676,902
636,779
672,862
667,335
677,243
602,043
993,064
817,995
752,800
703,709
777,350
760,601
846,595
834,388
1,114,353
1,095,209
1,095,2091,114,353834,388846,595760,601777,350703,709752,800817,995993,064602,043677,243667,335672,862636,779676,902667,886655,019965,065550,406534,910546,159599,530553,850749,271669,736313,051296,883259,23700225,073
       Short-term Debt 
1,197,472
1,197,472
0
0
89,482
89,171
99,227
199,820
21,715
37,852
38,051
38,288
36,954
346,945
47,075
46,198
55,680
42,357
43,705
45,449
46,037
46,349
131,130
106,572
104,639
145,221
166,477
122,512
227,624
228,665
451,646
241,021
241,021451,646228,665227,624122,512166,477145,221104,639106,572131,13046,34946,03745,44943,70542,35755,68046,19847,075346,94536,95438,28838,05137,85221,715199,82099,22789,17189,482001,197,4721,197,472
       Short Long Term Debt 
1,197,472
1,197,472
0
0
89,482
14,415
21,678
121,694
21,449
21,445
21,445
21,468
21,479
330,736
30,756
30,776
45,228
29,817
30,461
33,689
30,614
30,523
114,920
89,940
89,961
129,965
150,405
106,533
213,125
212,660
435,519
0
0435,519212,660213,125106,533150,405129,96589,96189,940114,92030,52330,61433,68930,46129,81745,22830,77630,756330,73621,47921,46821,44521,44521,449121,69421,67814,41589,482001,197,4721,197,472
       Accounts payable 
60,033
0
0
66,639
70,013
84,221
169,046
124,539
514,440
558,750
505,143
495,857
507,483
606,925
599,489
613,619
613,661
574,322
596,227
589,412
583,345
539,734
561,692
531,462
538,199
467,421
512,719
557,761
143,572
175,325
199,578
0
0199,578175,325143,572557,761512,719467,421538,199531,462561,692539,734583,345589,412596,227574,322613,661613,619599,489606,925507,483495,857505,143558,750514,440124,539169,04684,22170,01366,6390060,033
       Other Current Liabilities 
63,820
0
0
192,598
311
228,830
251
246,233
16,517
16,407
2,965
765
401,702
11,195
8,455
8,069
462,544
20,100
32,930
32,474
500,122
15,960
300,242
179,961
109,962
91,067
77,011
76,828
475,399
430,398
463,129
854,188
854,188463,129430,398475,39976,82877,01191,067109,962179,961300,24215,960500,12232,47432,93020,100462,5448,0698,45511,195401,7027652,96516,40716,517246,233251228,830311192,5980063,820
   > Long-term Liabilities 
1,159,566
0
0
1,398,198
1,420,588
1,392,187
2,935,366
2,917,458
2,902,523
2,985,275
2,966,628
2,773,309
2,768,696
3,022,277
3,030,721
3,021,454
2,984,199
2,956,583
2,959,919
2,923,908
2,895,448
2,879,518
2,857,465
3,033,669
2,837,613
2,760,701
2,740,662
2,735,098
2,605,963
2,638,616
2,399,636
2,399,449
2,399,4492,399,6362,638,6162,605,9632,735,0982,740,6622,760,7012,837,6133,033,6692,857,4652,879,5182,895,4482,923,9082,959,9192,956,5832,984,1993,021,4543,030,7213,022,2772,768,6962,773,3092,966,6282,985,2752,902,5232,917,4582,935,3661,392,1871,420,5881,398,198001,159,566
       Long term Debt Total 
0
0
0
0
0
0
2,680,525
2,675,108
2,669,681
2,687,408
2,681,778
2,678,131
2,674,509
2,871,963
2,764,578
2,757,139
2,735,264
2,728,212
2,720,117
2,687,668
2,680,053
2,672,661
2,622,447
2,607,217
2,591,981
2,561,724
2,589,737
0
0
0
0
0
000002,589,7372,561,7242,591,9812,607,2172,622,4472,672,6612,680,0532,687,6682,720,1172,728,2122,735,2642,757,1392,764,5782,871,9632,674,5092,678,1312,681,7782,687,4082,669,6812,675,1082,680,525000000
       Long term Debt 
1,159,566
0
0
0
1,395,261
1,392,187
2,641,305
2,675,108
2,630,598
2,625,152
2,619,788
2,614,412
2,609,046
2,807,310
2,800,239
2,757,139
2,735,264
2,728,212
2,757,341
2,687,668
2,680,053
2,672,661
2,661,303
2,607,217
2,591,981
2,601,852
2,589,737
2,582,815
2,427,451
2,419,600
2,177,578
0
02,177,5782,419,6002,427,4512,582,8152,589,7372,601,8522,591,9812,607,2172,661,3032,672,6612,680,0532,687,6682,757,3412,728,2122,735,2642,757,1392,800,2392,807,3102,609,0462,614,4122,619,7882,625,1522,630,5982,675,1082,641,3051,392,1871,395,2610001,159,566
       Capital Lease Obligations 
0
0
0
0
0
0
39,220
0
39,083
145,308
141,294
137,185
135,542
141,351
143,332
137,353
123,876
125,154
129,741
11,760
127,351
124,583
122,505
120,962
123,487
121,442
118,592
115,340
109,947
113,569
112,042
0
0112,042113,569109,947115,340118,592121,442123,487120,962122,505124,583127,35111,760129,741125,154123,876137,353143,332141,351135,542137,185141,294145,30839,083039,220000000
       Warrants
0
0
0
0
0
0
11,900
0
0
0
0
0
0
12,563
12,380
11,932
11,804
13,079
14,112
15,260
16,907
16,420
17,885
22,375
24,949
27,527
32,106
0
0
0
0
0
0000032,10627,52724,94922,37517,88516,42016,90715,26014,11213,07911,80411,93212,38012,56300000011,900000000
       Other Liabilities 
9,202
0
0
0
25,327
22,369
242,983
242,350
232,842
231,222
222,152
38,532
39,583
30,977
35,031
36,746
87,267
32,719
71,969
220,980
48,522
43,237
89,867
88,554
97,117
0
48,405
0
0
0
0
0
0000048,405097,11788,55489,86743,23748,522220,98071,96932,71987,26736,74635,03130,97739,58338,532222,152231,222232,842242,350242,98322,36925,3270009,202
       Long-term Liabilities Other 
0
0
0
0
0
0
240,467
240,589
231,664
231,222
222,152
38,532
39,583
7,892
10,721
252,383
237,131
215,292
63,255
220,980
198,488
190,437
79,213
232,163
245,632
41,456
39,282
41,388
8,215
91,481
90,496
0
090,49691,4818,21541,38839,28241,456245,632232,16379,213190,437198,488220,98063,255215,292237,131252,38310,7217,89239,58338,532222,152231,222231,664240,589240,467000000
       Deferred Long Term Liability 
0
0
0
0
0
0
2,491
1,761
1,178
0
0
0
3,099
3,434
3,174
2,908
2,648
0
0
0
1,603
1,345
2,453
2,356
2,206
0
1,926
0
0
0
0
0
000001,92602,2062,3562,4531,3451,6030002,6482,9083,1743,4343,0990001,1781,7612,491000000
> Total Stockholder Equity
-185,290
-185,290
0
-436,606
-385,739
0
494,501
501,105
896,363
472,205
459,656
395,724
346,788
318,376
305,995
301,040
344,932
323,015
346,107
383,166
366,973
391,125
172,991
297,469
183,979
134,668
150,768
154,236
19,781
-63,724
-57,465
-93,567
-93,567-57,465-63,72419,781154,236150,768134,668183,979297,469172,991391,125366,973383,166346,107323,015344,932301,040305,995318,376346,788395,724459,656472,205896,363501,105494,5010-385,739-436,6060-185,290-185,290
   Common Stock
2,675
0
0
2,716
2,716
0
2,985
2,986
2,987
2,989
2,991
2,991
2,992
2,994
2,996
2,997
2,997
3,007
3,012
3,014
3,014
3,028
3,032
3,035
3,036
3,054
3,062
3,064
3,066
3,086
3,095
0
03,0953,0863,0663,0643,0623,0543,0363,0353,0323,0283,0143,0143,0123,0072,9972,9972,9962,9942,9922,9912,9912,9892,9872,9862,98502,7162,716002,675
   Retained Earnings 0-575,825-581,819-490,176-391,527-401,209-413,126-406,183-401,850-399,161-278,353-276,197-269,820-265,583-280,115-286,821-283,784-274,809-262,813-377,880-345,752-80,746-63,844-20,920-12,152-19,104-357,980-382,785-424,35400-175,168
   Capital Surplus 
0
0
0
0
0
0
517,122
520,160
530,438
537,159
544,161
565,641
606,966
611,600
617,504
623,133
628,413
634,484
642,657
650,539
658,350
666,799
675,588
683,745
691,629
700,722
708,233
0
0
0
0
0
00000708,233700,722691,629683,745675,588666,799658,350650,539642,657634,484628,413623,133617,504611,600606,966565,641544,161537,159530,438520,160517,122000000
   Treasury Stock00000000000000000000000000000000
   Other Stockholders Equity 
-12,797
0
0
-14,968
8,562
357,980
517,122
520,160
530,438
537,159
544,161
565,641
606,966
611,600
617,504
623,133
628,413
634,484
642,657
650,539
658,350
666,799
568,252
683,745
577,187
540,976
150,768
154,236
539,240
538,720
545,701
556,196
556,196545,701538,720539,240154,236150,768540,976577,187683,745568,252666,799658,350650,539642,657634,484628,413623,133617,504611,600606,966565,641544,161537,159530,438520,160517,122357,9808,562-14,96800-12,797



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,393,607
Cost of Revenue-1,573,042
Gross Profit820,565820,565
 
Operating Income (+$)
Gross Profit820,565
Operating Expense-596,315
Operating Income204,374224,250
 
Operating Expense (+$)
Research Development167,778
Selling General Administrative429,675
Selling And Marketing Expenses0
Operating Expense596,315597,453
 
Net Interest Income (+$)
Interest Income0
Interest Expense-210,629
Other Finance Cost-40,805
Net Interest Income-251,434
 
Pretax Income (+$)
Operating Income204,374
Net Interest Income-251,434
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-40,270449,018
EBIT - interestExpense = 60,753
-75,541
126,636
Interest Expense210,629
Earnings Before Interest and Taxes (EBIT)271,382170,359
Earnings Before Interest and Taxes (EBITDA)500,782
 
After tax Income (+$)
Income Before Tax-40,270
Tax Provision-8,452
Net Income From Continuing Ops-48,722-48,722
Net Income-83,993
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,189,233
Total Other Income/Expenses Net-244,644251,434
 

Technical Analysis of Amneal
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Amneal. The general trend of Amneal is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Amneal's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Amneal Pharmaceuticals, Inc. Class A Common Stock.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.475.

The bearish price targets are: 8.01 > 7.52 > 6.5.

Tweet this
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current macd is -0.07240821.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Amneal price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Amneal. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Amneal price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Moving Average Convergence/Divergence (MACD) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current adx is 24.71.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Amneal shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current sar is 9.38619992.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current rsi is 44.59. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Relative Strength Index (RSI) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Amneal price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Stochastic Oscillator ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current cci is -53.95678911.

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Commodity Channel Index (CCI) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current cmo is -14.84962121.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Chande Momentum Oscillator (CMO) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current willr is -76.49006623.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Amneal is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Williams %R ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Amneal Pharmaceuticals, Inc. Class A Common Stock.

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current atr is 0.29623814.

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Average True Range (ATR) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current obv is -9,353,387.

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily On-Balance Volume (OBV) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current mfi is 43.50.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Money Flow Index (MFI) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Amneal Pharmaceuticals, Inc. Class A Common Stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Amneal Pharmaceuticals, Inc. Class A Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.592
Ma 20Greater thanMa 508.546
Ma 50Greater thanMa 1008.524